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Given the success in engineering synthetic pheno-
types in microbes and mammalian cells, construct-
ing non-native pathways in mammals has become
increasingly attractive for understanding and identi-
fying potential targets for treating metabolic disor-
ders. Here, we introduced the glyoxylate shunt into
mouse liver to investigate mammalian fatty acid
metabolism. Mice expressing the shunt showed
resistance to diet-induced obesity on a high-fat diet
despite similar food consumption. This was accom-
panied by a decrease in total fat mass, circulating
leptin levels, plasma triglyceride concentration, and
a signaling metabolite in liver, malonyl-CoA, that
inhibits fatty acid degradation. Contrary to plants
and bacteria, in which the glyoxylate shunt prevents
the complete oxidation of fatty acids, this pathway
when introduced in mice increases fatty acid oxida-
tion such that resistance to diet-induced obesity
develops. This work suggests that using non-native
pathways in higher organisms to explore and modu-
late metabolism may be a useful approach.
INTRODUCTION
The obesity epidemic is widespread in developed countries and
is associated with the constellation of clinical problems known
as the metabolic syndrome: insulin resistance, diabetes, cardio-
vascular disease, dyslipidemia, and fatty liver (Kahn et al., 2006;
Van Gaal et al., 2006). Elevated levels of plasma free fatty acids
are a risk factor for the development of type 2 diabetes (Paolisso
et al., 1995) and are a biochemical hallmark of obesity. Fatty
acids are used as an energy source in skeletal muscle and liver,
and their use is tightly controlled by several factors including
availability in the diet, de novo biosynthesis, glucose levels,
and gluconeogenesis. Fatty acid and triglyceride biosynthesis
is associated with high glucose concentrations and glycolytic
rates, while fatty acid degradation generally occurs during
periods of glucose starvation. Regulation of fatty acid biosyn-
thesis and degradation ensures that glucose is oxidized prefer-
entially before fatty acids in hepatocytes.Under normal circumstances the liver stores very little lipid
because hepatic lipogenesis is balanced with fatty acid degra-
dation. Fatty acid biosynthesis begins with transport of citrate
from the mitochondria to the cytosol where it is converted to
oxaloacetate (OAA) and acetyl-CoA by citrate lyase (ACLY).
The carboxylation of acetyl-CoA to malonyl-CoA by acetyl-CoA
carboxylase (ACC) represents the first committed step in fatty
acid biosynthesis. Hepatic fatty acids have two fates. They
may be incorporated into triglycerides, which are packaged
into very low-density lipoproteins and secreted into the blood
to deliver lipids to other tissues. Alternatively, fatty acids are
degraded via b-oxidation to generate reducing power and
energy. Hepatic fatty acid degradation is regulated by the cyto-
solic metabolites citrate and malonyl-CoA. The former is an allo-
steric activator of ACC (Saha et al., 1999), and the latter is
a potent inhibitor of carnitine palmitoyltransferse-1a (CPT1A)
(McGarry and Brown, 1997), which mediates the transport of
fatty acids into mitochondria for b-oxidation. High rates of fatty
acid b-oxidation are linked to a decrease in malonyl-CoA levels
and an increase in AMP-activated protein kinase (AMPK)-medi-
ated ACC covalent inactivation (Kudo et al., 1995). The product
of b-oxidation, acetyl-CoA, enters the TCA cycle.
Whereas adipose tissue is specialized to store lipids, excess
triglyceride storage in the liver is a pathologic condition. In
obesity, for example, the delivery of fatty acids liberated from
adipocytes to the liver may outpace the capacity of hepatocytes
for fatty acid oxidation, leading to triglyceride accumulation.
This, in turn, promotes the development of nonalcoholic fatty
liver disease, which is the most common cause of liver disease
and occurs in 20%–40% of obese subjects (Browning and
Horton, 2004; Farrell and Larter, 2006; Torres and Harrison,
2008; Youssef and McCullough, 2002). This suggests that
increased hepatic fatty acid oxidation may have a favorable
effect on comorbidities associated with obesity.
In this study, we exploit a metabolic pathway that is present in
plants and bacteria, but not normally found in mammals, to per-
turb the balance of energy homeostasis and attempt to gain
further insight into fatty acid oxidation in the liver. Since
mammals do not have this shunt, its effect on liver metabolism
cannot be predicted. In fact, opposite possibilities exist depend-
ing on the local context and cellular regulation. Remarkably, we
found that human hepatocytes expressing the glyoxylate shunt
have increased fatty acid oxidation, and mice expressing this
shunt in the liver were resistant to diet-induced obesity. TheseCell Metabolism 9, 525–536, June 3, 2009 ª2009 Elsevier Inc. 525
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Mice with Glyoxylate Shunt Resist Diet-Induced ObesityFigure 1. Hepatic Glyoxyate Shunt Expression Yields Multiple Possibilities with Distinct Phenotypes
Red lines represent the metabolic cycle for complete acetyl-CoA oxidation including the glyoxylate shunt enzymes, which are shaded orange. This pathway is
expected to increase fatty acid degradation by decreasing malonyl-CoA levels. The gray dashed lines represent alternative pathways, which include acetyl-CoA
incorporation into oxaloacetate for gluconeogenesis and malonyl-CoA for lipid biosynthesis, as well as the part of TCA cycle that is bypassed. The dashed green
line represents allosteric inhibition. Abbreviations: PDH, pyruvate dehydrogenase; CPT1a, carnitine palmitoyltransferse-1a; PEPCK, phosphoenolpyruvate car-
boxykinase; ME1, cytosolic malic enzyme.effects were attributed to the decreased malonyl-CoA level and
an additional oxidation pathway formed through the shunt and
cytosolic malic enzyme (ME1) and phosphoenolpyruvate car-
boxykinase (PEPCK). Therefore, we demonstrate the potential
benefit of using a non-native pathway to deliver a synthetic
phenotype and identify potential targets for therapy.
RESULTS
Possible Outcomes of Hepatic Glyoxylate
Shunt Expression
The glyoxylate shunt, isocitrate lyase (aceA) and malate syn-
thase (aceB), is a two-enzyme pathway that allows the cell to
conserve carbon by bypassing the oxidative CO2-producing
reactions of the TCA cycle. This carbon conservation allows
bacteria and plants to use fatty acids as a gluconeogenic
substrate and avoid the complete oxidation of fatty acids to
CO2. Regulation in plants and bacteria ensures that glyoxylate
shunt expression is repressed in the presence of glucose and
activated during growth on fatty acids.
Since mammals do not have the glyoxylate shunt, the result of
its activity on mammalian energy metabolism is unknown. We526 Cell Metabolism 9, 525–536, June 3, 2009 ª2009 Elsevier Inc.hypothesized at least three possible net outcomes of the conser-
vation of carbon metabolites that would occur by activating this
pathway (Figure 1): (1) four-carbon gluconeogenic substrates
would be generated and used for gluconeogenesis, similar to
plants and bacteria; (2) the four-carbon TCA cycle intermediated
would be converted to citrate, which would be exported from
mitochondria and converted into malonyl-CoA, which reduces
fatty acid degradation; or (3) the conserved carbon metabolite
would be oxidized through either cytosolic malic enzyme
(ME1) or phosphoenolpyruvate carboxykinase (PEPCK) and
pyruvate dehydrogenase (PDH) complex (additional details in
the Supplemental Data available online). The first two possibili-
ties are direct consequences of carbon saving due to bypassing
the decarboxylation part of the TCA cycle. Thus, these two
possibilities lead to either no change or decreased fatty acid
oxidation and a possible increase in cell mass. On the other
hand, the third possibility essentially provides an additional
pathway for complete fatty acid oxidation to CO2. This route
avoidsmalonyl-CoA build up and provides a favorable regulatory
state for fatty acid oxidation. Among these possibilities, the
cellular regulation in mammals will ultimately determine the
outcome of this non-natural perturbation.
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Have Increased Fatty Acid Degradation
To investigate these possibilities, we first constructed a stably
transfected human HepG2 hepatocyte cell line constitutively ex-
pressing the glyoxylate shunt genes, aceA and aceB, from E. coli
(designated ACE) (Figures 2A–2C). We found that ACE cells ex-
hibited higher palmitate uptake rates than WT cells, and this
phenotype persisted across a broad range of physiological fatty
acid levels up to 1 mM palmitate (Figure 2D). Here WT refers to
the HepG2 cell line stably transfected with an empty vector
pBudCE4.1. A stable cell line expressing lacZ was also gener-
ated and found to have the same palmitate uptake rate as the
WT cell line (data not shown). This phenotype was also demon-
strated using a fluorescence-based uptake assay (Liao et al.,
2005) employing fluorescently labeled dodecanoic acid bound
to bovine plasma albumin (Figure 2E). Interestingly, palmitate
taken up by ACE cells is not used for gluconeogensis, as evi-
denced by the lack of 13C-labeled glucose generated from
[U-13C] palmitate (Figure 2F), even though gluconeogenesis
was functional in ACE cells (Figures 2F and S1). Rather, ACE
cells were found to oxidize more than twice as much [U-14C]
palmitate to 14CO2 than WT (Figure 2G). Taken together, these
results demonstrate that ACE cells have increased overall fatty
acid oxidation compared to WT cells. In addition, we found
that ACE cells consumed less glucose (Figure 2H) and produced
less lactate (Figure S2) than WT cells over a range of palmitate
concentrations. In the absence of palmitate, ACE and WT cells
consumed identical amounts of glucose (Figure 2H).
ME1 Expression Is Necessary for ACE Phenotype
The glyoxylate shunt may create an additional cycle for oxidizing
acetyl-CoA (Figure 1) through either ME1 (Liao et al., 1996) or
PEPCK, and our results suggest that cells may use the shunt in
this manner to increase fatty acid degradation in the presence
of glucose. Since the cell culture metabolic studies were per-
formed in high-glucose media, we expect ME1, a lipogenic
enzyme (Stefos et al., 2009), to be the predominant pathway
for recycling TCA intermediates to pyruvate and allowing for
complete oxidation of fatty acids. According to this hypothesis,
the flux through ME1 is necessary for the increased fatty acid
degradation in ACE cells. To test this hypothesis, we used siRNA
to knockdown ME1 in both ACE and WT cells. Knockdown of
ME1 resulted in ACE and WT cells consuming identical amounts
of palmitate (Figures 2I and S3), abolishing the increased fatty
acid degradation observed in ACE cells and supporting our
conclusion that ME1 and the glyoxylate shunt created an addi-
tional pathway for acetyl-CoA oxidation.
ACE Cells Exhibit Posttranslational and Transcriptional
Changes Consistent with Metabolic Phenotype
We also investigated the effect of the glyoxylate shunt on signal
transduction pathways. In particular, phosphorylated AMPK,
designated pAMPK Thr172, was significantly increased in ACE
cells compared to WT (Figure 3A), despite similar AMPK protein
(Figure 3A) and mRNA levels. Activated phosphorylated AMPK
can inactivate ACC by phosphorylation on serine 79 (Park
et al., 2002), leading to decreased malonyl-CoA production
and decreased CPT1A inhibition. Examination of the levels of
active and inactive (designated pACC Ser79) forms of ACCrevealed that the active form was lower in ACE than in WT cells
and the inactive form was higher in ACE cells (Figure 3A). These
results suggest that the association between the phosphorylated
levels of AMPK and ACC play a role in allowing ACE cells to
metabolize fatty acid at a higher rate than WT. Taken together,
these signal transduction responses are consistent with the
observed ACE metabolic phenotype.
In addition to signal transduction and metabolic adaptations,
microarray analysis showed that ACE cells had a gene-expres-
sion profile that was consistent with the observed metabolic
phenotype (Figure 3B and Tables S1–S5). In particular, CTP1A,
which facilitates the transport of fatty acids from the cytoplasm
to the mitochondria, and fatty acid-CoA ligase (FACL3), an
enzyme involved in b-oxidation, were found to have a higher
expression level in ACE cells compared toWT. In addition, genes
involved in TG production were found to have markedly lower
expression levels in ACE cells compared to WT. Consistent
with the decreased glucose consumption observed, ACE cells
showed lower expression of genes from glycolysis. Furthermore,
micorarray analysis showed that uncoupling protein 2 (UCP2)
mRNA levels were higher in ACE cells than WT (2.38 ± 0.52)
(Tables S1–S5).
Mice Expressing the Glyoxylate Shunt Resist
Diet-Induced Obesity
To determine the effect of liver-specific glyoxylate shunt expres-
sion on whole-animal metabolism, we injected male and female
C57BL/6 mice into the tail vein with vectors containing either
aceA and aceB (designated ACE) or lacZ under control of
a liver-specific promoter andmonitored them for 6 weeks (Exper-
iment 1, Figure S4). Male and female mice were injected at 20 g
(6–7 weeks of age) and placed on a standard chow diet (LFD,
13.2% calories from fat, 4.07 kcal/g) or a high-fat diet (HFD,
60% calories from fat, 5.24 kcal/g) for 6 weeks. Plasma alanine
aminotransferse (ALT) levels, amarker for hepatocellular damage,
were normal for both male and female ACE and lacZ-injected
mice (Figure S5). Body weight wasmeasuredweekly for 6 weeks.
Four weeks postinjection, mice were fasted overnight and blood
was drawn retro-orbitally. Six weeks postinjection body compo-
sition was analyzed by nuclear magnetic resonance (NMR), after
which mice were sacrificed and tissues were collected.
Reverse-transcriptase PCR from liver, lung, and kidney shows
that glyoxylate shunt expression was specific to liver (Figure 4A),
active as determined by enzyme assay (Figure 4B), and main-
tained for the duration of diet experiments. We found that both
male and female ACE mice gained less weight on a HFD than
mice injected with lacZ (Figures 4C–4E and S6), and this resis-
tance to diet-induced obesity was significant after 3 weeks.
We found that female ACE mice weighed 5.2 g less than lacZ-
injected mice after 6 weeks on a HFD (Figures 4C and 4D), and
male ACE mice weighed 2.6 g less than the lacZ-injected mice
(Figure 4E). Conversely, the glyoxylate shunt has little effect on
mice fed a LFD. Female (Figure 4D) and male (Figure 4E) ACE
mice were found to gain similar or slightly less weight over the
course of 6 weeks on a LFD compared to the lacZ-injected mice.
ACE Mice Have Decreased Total Body Fat
We also found that glyoxylate shunt expression led to significant
changes in body composition in female mice. Female ACE miceCell Metabolism 9, 525–536, June 3, 2009 ª2009 Elsevier Inc. 527
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Figure 2. Human HepG2 Hepatocytes Express-
ing the Glyoxyate Shunt Have Increased Fatty
Acid Degradation
(A) Reverse transcriptase PCR products from ACE
cells (lanes 1 and 4) and WT cell lines (lanes 2 and 3)
were run on a 1% agarose gel. The sizes of the
ACEA (1.3 kb) and ACEB (1.6kb) mRNA are shown
(lanes 1 and 4 respectively).
(B) Western blot analysis of protein extracts from ACE
(lanes 1 and 3) and WT (lanes 2 and 4) cells indicating
the 61 kDa ACEA and the 48 kDa ACEB proteins.
(C) Enzyme assay shows that the glyoxylate shunt was
active in ACE cells. Mean ± SEM.
(D) Fatty acid uptake rate over a range of palmitate
concentrations for both ACE (closed squares) and
WT (open squares). *p < 0.05 compared to corre-
sponding WT control; mean ± SEM; n = 3–6.
(E) Fatty acid uptake assay using fluorescently labeled
dodecanoic acid confirms that the ACE cells take up
fatty acids more rapidly thanWT. Image is representa-
tive of two experiments.
(F) Gluconeogenesis was assessed by measuring
[U-13C] glycerol and [U-13C] palmitate incorporation
into glucose. The glucose pentacetate derivative
containing glucose carbons 2–6 was analyzed with
GC-MS. ACE cells incorporate [U-13C] glycerol into
glucose, as evidenced by the increased 13C enrich-
ment in glucose.
(G) [U-14C] palmitate was used to measure palmitate
oxidation to CO2. WT was used a normalization basis.
*p < 0.05 compared to corresponding WT control;
mean ± SEM; n = 3.
(H) Glucose uptake over a range of palmitate concen-
trations for both ACE (closed squares) and WT (open
squares). ACE cells consume less glucose than WT
cells. *p < 0.05 compared to corresponding WT con-
trol. Mean ± SEM; n = 3–6.
(I) Palmitate uptake for ACE ME1 knockdown (ACE-
ME1-KD) and WT ME1 knockdown (WT-ME1-KD).
ME1 KD results in ACE and WT cells consuming iden-
tical amounts of palmitate. Mean ± SEM; n = 6.528 Cell Metabolism 9, 525–536, June 3, 2009 ª2009 Elsevier Inc.
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Mice with Glyoxylate Shunt Resist Diet-Induced Obesitywere found to have 28% body fat and lacZ-injected mice 36%
after 6 weeks on HFD (Figures 4F and 4G). In addition, fat
mass was reduced in female ACE mice by more than 4 g,
accounting for over 80% of the weight difference between ACE
and lacZ-injected mice (Figure 4F). On LFD, female ACE mice
were found to have 8% body fat and lacZ-injected mice 11%
A
B
Figure 3. Posttranslational and Gene Expression Changes in ACE
Cells Are Consistent with Increased Fatty Acid Degradation
(A) Western blot analysis of WT (left panel) and ACE (right panel) cell lines. ACE
and WT cells were given DMEM supplemented with 300 mM palmitate, and
protein was harvested at various time points over 24 hr. Blots are representa-
tive of two experiments.
(B) Metabolic networks related to glucose and fatty acid metabolism. Microar-
ray analysis showing relative (fold change) gene-expression levels in the genes
involved in glycolysis, fatty acid b-oxidation, and triglyceride synthesis from
ACE and WT cell lines. Positive numbers indicated that the ACE cell line had
higher expression levels than WT and are indicated by red arrows. Negative
numbers indicate that the ACE cell line had lower expression levels and are
indicated by green arrows. Data are represented as mean ± SEM; n = 2.
Dashed green line represents allosteric regulation; malonyl-CoA inhibits
CPT1a. Abbreviations are listed in Table S1. Key enzymes are shown in blue
circles: malic enzyme (ME1), pyruvate dehydrogenase (PDH), pyruvate
carboxylase (PC), acetyl-CoA carboxylase (ACC), and carnitine palmitoyl-
transferse-1a (CPT1A).(Figures 4F and 4G) even though there was not a significant
difference in body weight. Although male ACE mice gained
less weight on both HFD and LFD than lacZ-injected mice, there
was not a significant difference in body fat percentage (Fig-
ure 4G). However, male ACE mice on HFD gained significantly
less fat mass than lacZ-injected mice (Figure 4F).
Female ACE Mice Accumulate Less Visceral Fat
and Have Decreased Circulating Leptin Levels
Our results indicate that the glyoxylate shunt exerts a greater
effect on female mice than male mice even though female and
male mice displayed similar levels of aceA and aceB gene
expression (Figure S7). This may be related to the inherent sexu-
ally dimorphic properties of fatty acid metabolism (Jalouli et al.,
2003; Luxon and Weisiger, 1993; Sheorain et al., 1979) and
may be partially attributed to hormonal differences. Because of
the more dramatic phenotype seen in female mice on HFD, we
chose to study this group in more detail. Female mice were in-
jected at 7 weeks of age as described above and then placed
on aHFD. Twoweeks postinjection, micewere analyzed inmeta-
bolic cages to assess the effects of glyoxylate shunt expression
on energy expenditure, respiratory exchange ratio, and activity.
Six weeks after injection, blood and tissues were collected for
analysis (Experiment 2, Figure S8).
Visceral fat, adipose tissue stored in the intra-abdominal area,
is associated with type 2 diabetes and atherosclerosis (Tran
et al., 2008). After dissection of the animals, we found signifi-
cantly smaller visceral fat pads in female ACE mice (Figure 5A).
We also found that a smaller percentage of body weight is attrib-
uted to visceral fat in female ACE mice compared to lacZ-
injected mice (Figure 5B). Consistent with this result, female
ACE mice had decreased circulating levels of the adipokine
leptin (Figure 5C).
Female ACE Mice Have Decreased Liver
Malonyl-CoA and ATP Levels
As demonstrated, the glyoxylate shunt may create an alternate
cycle for acetyl-CoA oxidation (Figure 1). The key feature of
this pathway is that it avoids malonyl-CoA production and is ex-
pected to increase fatty acid degradation. We found that female
ACE mice had decreased liver malonyl-CoA levels compared to
lacZ-injectedmice on HFD (Figure 6A). This indicates that female
ACE mice may resist diet-induced obesity in part due to
decreased liver malonyl-CoA and therefore decreased CPT1a
inhibition. On LFD, female ACE mice were found to have
decreased liver malonyl-CoA, although the difference was not
significant. The glyoxylate shunt bypasses isocitrate dehydroge-
nase, 2-oxoglutarate dehydrogenase, and succinyl-CoA ligase,
enzymes producing reducing equivalents and ATP. We found
decreased liver ATP levels (Figure 6B) in female ACE mice
compared to lacZ-injected mice, indicating that the glyoxylate
shunt functions to bypass the oxidative portion of the TCA cycle.
This result may also explain the observed AMPK activation
(Figure 3A) in our hepatocyte culture model.
Female ACE Mice Have Decreased Liver and Plasma
Trigylceride Levels
Hepatic TG accumulation, often associated with insulin resis-
tance (Yki-Jarvinen, 2005), was found to be slightly lower inCell Metabolism 9, 525–536, June 3, 2009 ª2009 Elsevier Inc. 529
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Figure 4. Mice Expressing the Glyoxyate
Shunt in the Liver Resist Diet-Induced
Obesity and accumulate Less Fat Mass on
an HFD
(A) aceA and aceBwere present exclusively in liver
tissue as determined by reverse-transcriptase
PCR at the end of diet experiments.
(B) The glyoxylate shunt was functional in ACE
mice, as determined by enzyme assay. Mean ±
SEM.
(C) Female ACE and lacZ-injected mice after
6 weeks on HFD. Female ACE mice gain less
weight than lacZ-injected mice.
(D) Weight gain over 6 weeks for LFD and HFD for
female mice. *p < 0.05 compared to correspond-
ing lacZ-injected mouse on same diet; mean ±
SEM; n = 4–6.
(E) Weight gain over 6 weeks for LFD and HFD for
male mice. *p < 0.05 compared to corresponding
lacZ-injected mouse on same diet; mean ± SEM;
n = 4–6.
(F) Body composition as assessed at the conclu-
sion of diet experiments using NMR. Female ACE
mice have decreased total fat mass after 6 weeks
on both LFD and HFD. *p < 0.05 for ACE fat mass
compared to lacZ-injected mouse fat mass.
Mean ± SEM; n = 4–6.
(G) Body fat percentage for ACE and lacZ-injected
mice. Female ACE mice have decreased body fat
percentage. *p < 0.05 compared to corresponding
lacZ-injected mouse on same diet; mean ± SEM;
n = 4–6.530 Cell Metabolism 9, 525–536, June 3, 2009 ª2009 Elsevier Inc.
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Mice with Glyoxylate Shunt Resist Diet-Induced Obesityfemale ACE mice as determined by liver TG content (Figure 6C).
Analysis of plasma revealed that female mice expressing the
glyoxylate shunt have different metabolite profiles than those ex-
pressing lacZ (Figure 6D). Female ACE mice were found to have
lower triglyceride plasma concentrations than lacZ-injected
mice after 4 weeks on a HFD (Figure 6D). Female ACE mice on
a HFD were also found to have decreased plasma total choles-
terol concentrations than lacZ-injected mice (Figure 6D). Since
acetyl-CoA is the precursor for hepatic cholesterol biosynthesis,
the glyoxylate shunt may lower cholesterol levels by providing an
alternate acetyl-CoA consuming pathway. We did not find
a difference in free fatty acid or glucose levels (Figure 6D).
Female ACE mice were found to have lower plasma concentra-
tions of the ketone body 3-hydroxybutyrate (Figure 6E). Keto-
genesis is typically proportional to fatty acid oxidation rates
(Beylot, 1996) and mitochondrial acetyl-CoA levels. ACE mice
may have lower circulating ketone body levels despite increased
hepatic fatty acid oxidation due to glyoxylate shunt consumption
A
B
C
Figure 5. Female ACE Mice Have Smaller Visceral Fat Pads and
Decreased Circulating Leptin
(A) Female ACE mice accumulated less intra-abdominal fat pads compared to
lacZ-injected mice.
(B) Visceral fat mass expressed as percent body weight for female mice on
HFD. *p < 0.05; mean ± SEM; n = 4.
(C) Female ACE mice showed lower circulating plasma leptin concentrations
as determined by ELISA. *p < 0.05; mean ± SEM; n = 3–4.of acetyl-CoA, the ketone body precursor substrate. We found
no difference in plasma insulin levels (Figure S9).
Female ACE Mice Have Increased CPT1a and PEPCK
Gene Expression
We next examined the effect of glyoxylate shunt expression on
mRNA levels of enzymes from the fatty acid degradation and
gluconeogenic pathways. Female ACE mice were found to
have increased expression of UCP2 and CPT1a (Figure 6F),
congruous with our cell-culture microarray analysis. While these
results indicate increased hepatic fatty acid oxidation in ACE
mice, we found no difference in the mRNA levels of glucose-6-
phosphatase (Figure 6F), an enzyme catalyzing the final step in
gluconeogensis. This result coupled with the finding that ACE
and lacZ-injected mice have identical fasting plasma glucose
concentrations (Figure 6D) further supports our conclusion that
the glyoxylate shunt does not function as a gluconeogenic
pathway in hepatocytes.
Female ACE mice were also found to have increased PEPCK
mRNA levels (Figure 6F). This suggests that a cycle through
PEPCK and the glyoxylate shunt for complete acetyl-CoA oxida-
tion to CO2 is functional in vivo (Figure 1). This is in contrast to our
cell-culture model, where ME1 was implicated in a similar cycle
(Figure 2I). A possible explanation for this difference is that mice
were subjected to an overnight fast before tissue collection,
a state that has been shown to increase PEPCK expression
(Granner and Pilkis, 1990; Patsouris et al., 2004).
Glyoxyate Shunt Expression Does Not Affect
Food Intake
Metabolic cages were used to assess the effect of the glyoxylate
shunt on basal oxygen consumption, feeding, and activity.
Female ACE and lacZ mice 2 weeks postinjection on a HFD dis-
played similar total food intake normalized for body weight
(Figure 7A), demonstrating that the lower body weight of ACE
mice is not due to decreased food consumption.
Female ACE Mice Have Decreased Respiratory
Exchange Ratio
Respiratory exchange ratio (RER), a ratio of carbon dioxide
production to oxygen consumption and an indicator of relative
total body carbohydrate and fatty acid oxidation, was slightly
lower in ACE mice during both the dark and light cycles as well
as over the entire 24 hr period (Figure 7B) of analysis. An RER
of 1.00 corresponds to ‘‘pure’’ carbohydrate oxidation (100%
of total O2 consumed by metabolism of carbohydrate, 0%
from fat), while an RER of 0.70 represents ‘‘pure’’ fatty acid
oxidation (100% of total O2 consumed by metabolism of fat,
0% from carbohydrate). Thus, the decreased RER in ACE mice
is indicative of increased total body fatty acid oxidation. This
result may partially explain the decreased fat and hepatic TG
accumulation in ACE mice (Figures 4F, 4G, and 6C). Female
ACEmice also had a small increase in energy expenditure during
the light cycle and over the entire 24 hr period (Figure 7C). ACE
and lacZ-injected mice displayed similar oxygen consumption
(Figure 7D) and ambulatory activity (Figure 7E).Cell Metabolism 9, 525–536, June 3, 2009 ª2009 Elsevier Inc. 531
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Non-native pathways have been used to engineer novel biolog-
ical functions and complex dynamics in both microbial (Atsumi
et al., 2008; Elowitz and Leibler, 2000; Fung et al., 2005; Gard-
ner et al., 2000; Kobayashi et al., 2004) and mammalian (Deans
et al., 2007; Kramer et al., 2004; Tigges et al., 2009; Weber et al.,
2006) systems. This strategy offers new opportunities for
A B
C D
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Figure 6. The Glyoxylate Shunt Decreases
Liver Malonyl-CoA and Triglyceride Levels
(A) Female ACE mice on HFD had lower liver ma-
lonyl-CoA levels on HFD. ACE mice may resist
diet-induced obesity in part due to decreased liver
malonyl-CoA and therefore decreased CPT1a
inhibition. *p < 0.05 compared to corresponding
lacZ-injected mouse on same diet; mean ± SEM;
n = 3–4.
(B) Glyoxyate shunt expression led to decreased
total ATP levels in the liver, presumably due to by-
passing the oxidative portion of the TCA cycle. *p <
0.05; mean ± SEM; n = 4.
(C) Female ACE mice had decreased liver TG
content. *p < 0.05; mean ± SEM; n = 4.
(D) Plasma analysis of metabolites for female ACE
and lacZ-injected mice on HFD. Mice were fasted
overnight before blood was collected. ACE mice
had decreased triglyceride and total cholesterol
levels. Fasting glucose levels were identical, sug-
gesting that the glyoxyate shunt does not serve
a gluconeogenic function in the liver. *p < 0.05;
mean ± SEM; n = 4–6.
(E) Plasma concentrations of ketone body 3-hy-
droxybutyrate in female ACE and lacZ-injected
mice on HFD after overnight fast. *p < 0.05;
mean ± SEM; n = 3.
(F) Quantitative RT-PCR analysis of female ACE
and lacZ-injected mice on HFD. Mice were fasted
overnight and tissues were collected. ACE mice
have increased mRNA levels of UCP2 and
CPT1a, indicative of increased fatty acid oxidation.
Additionally, ACE mice had increased PEPCK
expression, suggesting that the glyoxylate shunt
and PEPCK form a cycle for acetyl-CoA oxidation
in vivo. *p < 0.05; mean ± SEM; n = 3–4. Abbrevia-
tions: G6Pase, glucose-6-phosphatase; PEPCK,
phosphoenolpyruvatecarboxykinase;PPARa, per-
oxisome proliferator-activated receptor a; UCP2,
mitochondrial uncoupling protein 2; CPT1a, carni-
tine palmitoyltransferse-1a; MCAD, medium-chain
acyl-CoAdehydrogenase; AOX, acyl-CoAoxidase.
studying metabolic networks and, when
applied to mammals, whole-body meta-
bolism. To investigate fatty acid metabo-
lism and identify potential targets for
treating obesity, we introduced a non-
native pathway, the glyoxylate shunt
from E. coli, into mouse liver. Here we
report that expression of this pathway
ameliorates many of the metabolic para-
meters associated with obesity by in-
creasing fatty acid degradation and decreasing total fat mass
accumulation.
Since mammals do not normally have the glyoxylate shunt, its
effect on lipid metabolism was unknown. We hypothesized that
expression could lead to increased or decreased fatty acid
degradation based on how the cell adapted to these enzymes.
In addition, hepatocytes could also use the pathway for gluco-
neogenesis, similar to how plants and bacteria use the shunt.532 Cell Metabolism 9, 525–536, June 3, 2009 ª2009 Elsevier Inc.
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Mice with Glyoxylate Shunt Resist Diet-Induced ObesityWe first tested the effect of glyoxylate shunt expression in
HepG2 hepatocytes and found that expression led to increased
fatty acid degradation compared to WT cells (Figures 2D, 2E,
and 2G). Furthermore, knocking down ME1 abolished the
increased fatty acid uptake observed in ACE cells (Figure 2I).
These results suggest that hepatocytes adapted to the non-
native pathway by creating an alternate cycle through aceA,
aceB, and ME1 for complete acetyl-CoA oxidation to CO2 and
that the glyoxylate shunt functions differently in hepatocytes
than plants and bacteria, where it is used to conserve carbon.
We next investigated the effect of the glyoxylate shunt on
whole-body metabolism by tail-vein-injecting vectors containing
aceA and aceB into mice. ACE mice gained less weight after 6
weeks on an HFD than lacZ-injected mice (Figures 4C–4E),
and this was accompanied with a decrease in fat mass accumu-
lation (Figures 4F–4G). We also found that the majority of the
weight difference between ACE and lacZ-injected female mice
was due to fat mass (Figure 4F). Female ACE mice accumulated
less visceral fat than lacZ-injected mice (Figures 5A and 5B), and
this resulted in decreased circulating leptin levels (Figure 5C).
These results demonstrate that the glyoxylate shunt effectively
alters whole-body lipid metabolism.
Since the glyoxylate shunt exerted such a significant effect on
lipid homeostasis, we investigated the intracellular levels of key
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Figure 7. ACE Mice Have Decreased RER and
Increased Energy Expenditure
(A) ACE and lacZ-injected mice consumed the same
amount of food normalized to body weight. Mean ±
SEM; n = 7–8.
(B) ACE mice had decreased RER during light, dark, and
total 24 hr period, suggesting increased fat oxidation.
*p < 0.05 compared to corresponding lacZ-injected
mouse during same period; mean ± SEM; n = 7–8.
(C) ACE mice demonstrated increased energy expendi-
ture, which may partially explain decreased weight gain
observed in ACEmice. *p < 0.05 compared to correspond-
ing lacZ-injected mouse during same period; mean ±
SEM; n = 7–8.
(D) ACE and lacZ-injected mice had similar oxygen
consumption levels. Mean ± SEM; n = 7–8.
(E) ACE and lacZ-injected mice had similar levels of
activity. Mean ± SEM; n = 7–8.
metabolites to further understand the underlying
mechanism of decreased fat storage in ACE
mice. We found that ACE mice had decreased
levels of plasma triglycerides (Figure 6D), likely
a consequence of increased fatty acid oxidation
and decreased adipose accumulation. Addi-
tionally, ACE mice were found to have de-
creased plasma cholesterol levels (Figure 6D).
Since acetyl-CoA is a precursor for cholesterol
biosynthesis, the glyoxylate shunt may
decrease cholesterol levels by providing an
additional acetyl-CoA-consuming pathway.
Alternatively, the glyoxylate shuntmay decrease
the available TG for VLDL and lead to apoB
destabilization, negatively affecting cholesterol
plasma concentrations. Although glyoxylate
shunt activity relative to other pathways was not assessed, we
found that the enzyme activity generated by tail-vein injection
was sufficient to perturb whole-body adipose accumulation
and plasma lipid concentrations.
Consistent with our hypothesis that the glyoxylate shunt
creates an alternate cycle for acetyl-CoA oxidation through the
shunt and either PEPCK or ME1 and diverts citrate transport
out of the mitochondria, we found that female ACE mice had
lower malonyl-CoA levels, a fatty acid b-oxidation inhibitor, on
an HFD than lacZ-injected mice (Figure 6A). Individual metabo-
lites have previously been found to regulate whole-body meta-
bolic profiles (An et al., 2004). Decreasing hepatic malonyl-CoA
levels by overexpressing malonyl-CoA decarboxylase, a cyto-
solic enzyme catalyzing the conversion of malonyl-CoA to
acetyl-CoA, reverses insulin resistance (An et al., 2004). Here
we find that decreasing malonyl-CoA levels via the glyoxyate
shunt reduces whole-body adiposity. Total liver ATP levels
were also markedly lower in ACE mice (Figure 6B). This may
be attributed to the shunt bypassing the oxidative portion of
the TCA cycle and the possibility that the NADH produced by
cytosolic malate dehydrogenase (Figure 1) was oxidized in
producing lactate rather than shuttling back into mitochondria.
However, other unknown mechanisms may exist for decreasing
the cell’s capacity for oxidative phosphorylation. This decreaseCell Metabolism 9, 525–536, June 3, 2009 ª2009 Elsevier Inc. 533
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Mice with Glyoxylate Shunt Resist Diet-Induced Obesityin ATP may explain the observed AMPK activation in ACE cells
(Figure 3A). Activated AMPK responds to low energy states by
activating ATP producing pathways and inhibiting energy
consuming pathways such as fatty acid biosynthesis (Long
and Zierath, 2006). This suggests that despite increased fatty
acid oxidation, ACE cells generate less energy per fatty acid
oxidized than WT. This energy dissipation is similar to the mech-
anism by which uncoupling proteins regulate the whole-body
energy balance. Uncoupling proteins decrease metabolic effi-
ciency by dissipating the proton gradient in the mitochondria,
causing energy created from metabolism to be released as
heat. Mice overexpressing UCP in skeletal tissue resist diet-
induced obesity (Li et al., 2000) and have improved insulin sensi-
tivity. Moreover, liver-specific UCP1 expression leads to
increased energy expenditure and decreased liver triglyceride
content (Ishigaki et al., 2005). So, similar to uncoupling proteins,
the glyoxylate shunt may alter the energy state of the cell in part
by decreasing the energy produced from fatty acid oxidation.
To further characterize the female ACE phenotype, we as-
sessed energy expenditure and whole-body substrate oxidation
using metabolic cages. Although ACE mice gained less weight
over the course of 6 weeks on an HFD, we found no difference
in food intake between ACE and lacZ-injected mice
(Figure 7A). Instead, we found ACE mice had a decreased RER
compared to lacZ-injected mice (Figure 7B), indicative of
increased fatty acid oxidation. This shows that ACE mice gain
less weight on an HFD because of increased fat oxidation and
not because of energy intake. This also demonstrates that the
glyoxyate exerts its effect on whole-body metabolism peripher-
ally and not through modulation of satiety sensations. ACE mice
had increased energy expenditure during the total 24 hr and light
period (Figure 7C) of analysis, indicating that ACE mice weigh
less than lacZ-injected mice, despite similar food intake, in
part because of increased energy expenditure.
Multiple mouse models exhibiting resistance to diet-induced
obesity have been documented (Abu-Elheiga et al., 2003; Elche-
bly et al., 1999; Li et al., 2000; Phan et al., 2004; Vergnes et al.,
2006; Zigman et al., 2005; Ziouzenkova et al., 2007). Here we
demonstrate such a model generated by expression of the
glyoxylate shunt from E. coli. Mice expressing this pathway
had decreased liver malonyl-CoA and ATP levels and a signifi-
cant decrease in percentage body fat. Bacteria and plants use
the glyoxyate shunt to conserve carbon by bypassing the decar-
boxylation steps of the TCA cycle, allowing glucose production
from fatty acids. In contrast, we found the shunt functioned
differently in mammals by increasing fatty acid oxidation. This
work suggests that using non-native metabolic pathways to
understand and exploremammalianmetabolismmay be a useful
approach. Finally, since ACE mice only partially resist diet-
induced obesity, our model may have advantages for studying
nonsevere forms of obesity.
EXPERIMENTAL PROCEDURES
Additional method details can be found in the Supplemental Data.
Plasmid Construction
Isocitrate lyase (aceA) and malate synthase (aceB) were cloned from E. coli
genomic DNA and fused with a mitochondria leader sequence. Genes were
cloned into pBudCE4.1 (Invitrogen) (designated pBudaceAB) and stably534 Cell Metabolism 9, 525–536, June 3, 2009 ª2009 Elsevier Inc.transfected into human hepatoma cell line HepG2. Genes aceA and aceB
were cloned separately from pBudaceAB into pLIVE vector (Mirus Bio;
Madison, WI).
Cell Culture
Human hepatoma cell line, HepG2 (American Type Culture Collection) was
maintained in DMEM supplemented with 10% heat-inactivated FBS and
50 mg/mL penicillin, 50 mg/mL streptomycin, and 100 mg/mL neomycin at
37C in a humidified atmosphere containing 5% CO2. Cells were transfected
in 60 mm plates with pBudaceAB or pBudCE4.1 with Lipofectamine 2000
(Invitrogen; Carlsbard, CA) according to manufacturer’s protocols. Colonies
were selected with DMEM supplemented with 320 mg/mL Zeocin (Invitrogen;
Carlsbard, CA). Enzyme assays were performed as described elsewhere (Chell
et al., 1978; Sundaram et al., 1980).
Metabolite Analysis
Metabolites were quantified using high-performance liquid chromatography
(HPLC) on an Agilent 1100model (Agilent Technologies; Palo Alto, CA) consist-
ing of a binary pump, autosampler, and degasser connected to an organic acid
Aminex HPX-87H column (3003 7.8 mm, Bio-Rad). Glucose was converted to
pentacetate derivative for GC-MS analysis (Tserng and Kalhan, 1983). Fatty
acid uptake assays were performed as previously documented (Liao et al.,
2005). Production of 14CO2 was measured as previously described (Harwood
et al., 2003) using [U-14C] palmitate. Plasma metabolite concentrations were
determined as described elsewhere (Castellani et al., 2008). Liver TG content
was measured using a triglyceride determination kit (Wako Diagnostics;
Richmond, VA). Malonyl-CoA was measured using [1-14C] acetyl CoA and
purified fatty acid synthase according to the method of McGarry (McGarry
et al., 1978). ATP measurement using a bioluminescence-based assay has
been described elsewhere (Evans et al., 2008). 3-hydroxybutyrate was
measured using an Autokit 3-HB (Wako Diagnostics; Richmond, VA).
siRNA ME1 Knockdown
Malic enzyme 1 (ME1) knockdown was performed using a RNAi Human Starter
Kit (QIAGEN; Valencia, CA) by transfecting the following siRNA duplex: r(GAA
CAA AUU CUC AAA GAU A)d(TT). Quantitative RT-PCR was performed using
SYBR Green chemistry and Smart Cycler (Cephied; Sunnyvale, CA) and fold
changes were calculated using DDCt method (Livak and Schmittgen, 2001)
with b-actin as an endogenous control. Transfection of a nonsilencing fluores-
cent siRNA had no effect on phenotype.
Microarray Analysis
Our data was submitted to the NCBI Gene Expression Omnibus in MIAME
format with access number GSE5903. The data can be accessed at
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=tzqrpeciomgaqzy&acc=
GSE5903.
Isolated total RNA samples were processed using HGU-133A_2 arrays as
recommended by Affymetrix, Inc. (Affymetrix GeneChip Expression Analysis
Technical Manual, Affymetrix, Inc.; Santa Clara, CA). The results were quanti-
fied and analyzed using GCOS 1.2 software (Affymetrix, Inc.) using default
values. Expression fold changes were calculated using dChip software (Zhong
et al., 2003), and results were filtered using a 90% confidence bound of fold
change. Expression changes were verified using RT-PCR (Table S5).
Western Blot
Western blot was performed using standard techniques. For time-course
experiments, ACE and WT cells were given DMEM supplemented with
300 mM palmitate and protein was harvested at various time points over
24 hr. Primary antibody incubation was overnight at 1:1000 dilution at 4C
and secondary antibody incubation was at 1:10,000 dilution for 1 hr at
room temperature. Antibodies were from Invitrogen and Cell Signaling
(Danvers, MA).
Animal Experiments
All animal procedures and care were per an institutional ARC-approved
protocol. Male and female C57BL/6 mice (Taconic; Hudson, NY) were housed
in cages of 1–4 at 22–24C with a 12 hr light/dark cycle with food and water
provided ad libitum. Genes aceA and aceB were cloned separately from
Cell Metabolism
Mice with Glyoxylate Shunt Resist Diet-Induced ObesitypBudaceAB into pLIVE vector (Mirus Bio; Madison, WI) and tail vein injected
(Alino et al., 2003; Bates et al., 2006; Huang et al., 2006) when mice were 6–
7 weeks of age. At 6–7 weeks of age mice were injected with either ACEAB
or lacZ and placed on a low fat chow or high-fat diet.
Quantitative RT-PCR
Total RNA was isolated female ACE and lacZ mouse liver after overnight fast
using RNeasy-plus columns (QIAGEN; Valencia, CA). First-strand cDNA was
synthesized using Superscript III Reverse Transcriptase (Invitrogen; Carlsbad,
CA). Quantitative RT-PCR was performed using SYBR Green Chemistry,
Quantitect Primer Assays (QIAGEN; Valencia, CA), and Smart Cycler (Cephied;
Sunnyvale, CA), and fold changes were calculated using DDCt method (Livak
and Schmittgen, 2001) with b-actin as an endogenous control.
Fat Pad and Leptin Analysis
Visceral fat pads from female ACE and lacZ mice were removed and weighed
after 6 weeks on an HFD. Blood was drawn after an overnight fast and leptin
was measured using ELISA (Crystal Chem; Downers Grove, IL).
Metabolic Cages
Animals were housed individually in a series of eight, airtight chambers
designed to assess the metabolic activity of mice over three 12 hr light/12 hr
dark cycles (Oxymax, Columbus Instruments, Columbus, OH). Animals were
acclimated to the chambers over the first 48 hr, and data were collected
over the subsequent 24 hr. The mice had free access to water and powdered
food presented from a food hopper attached to a scale. The rate of oxygen
consumption (VO2) and carbon dioxide production (VCO2) were calculated
and averaged over the entire final 24 hr period as well as for the light and
dark cycle for each mouse. Energy expenditure (EE) was calculated as previ-
ously described (Bohlooly et al., 2005) using the equation EE (Kcal/kg/hr) =
(3.815 + 1.232 3 RER) 3 VO2 where VO2 is the volume of oxygen consumed
per hour normalized to body weight and RER represents VCO2/VO2.
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